TNFRSF13B gene mutation in familial acute myeloid leukemia: A new piece in the complex scenario of hereditary predisposition?

IF 3.3 4区医学 Q2 HEMATOLOGY

Hematological Oncology Pub Date : 2023-08-03 DOI:10.1002/hon.3212

Cosimo Cumbo, Paola Orsini, Francesco Tarantini, Luisa Anelli, Antonella Zagaria, Vincenzo Tragni, Nicoletta Coccaro, Giuseppina Tota, Elisa Parciante, Maria Rosa Conserva, Immacolata Redavid, Crescenzio Francesco Minervini, Angela Minervini, Immacolata Attolico, Mattia Gentile, Ciro Leonardo Pierri, Giorgina Specchia, Pellegrino Musto, Francesco Albano

{"title":"TNFRSF13B gene mutation in familial acute myeloid leukemia: A new piece in the complex scenario of hereditary predisposition?","authors":"Cosimo Cumbo, Paola Orsini, Francesco Tarantini, Luisa Anelli, Antonella Zagaria, Vincenzo Tragni, Nicoletta Coccaro, Giuseppina Tota, Elisa Parciante, Maria Rosa Conserva, Immacolata Redavid, Crescenzio Francesco Minervini, Angela Minervini, Immacolata Attolico, Mattia Gentile, Ciro Leonardo Pierri, Giorgina Specchia, Pellegrino Musto, Francesco Albano","doi":"10.1002/hon.3212","DOIUrl":null,"url":null,"abstract":"TNFRSF13B mutations are widely associated with common variable immunodeficiency. TNFRSF13B was recently counted among relevant genes associated with childhood-onset of hematological malignancies; nonetheless, its role in acute myeloid leukemia (AML) remains unexplored. We report the study of a family with two cases of AML, sharing a germline TNFRSF13B mutation favoring the formation of a more stable complex with its ligand TNFSF13: a positive regulator of AML-initiating cells. Our data turn the spotlight onto the TNFRSF13B role in AML onset, inserting a new fragment into the complex scenario of a hereditary predisposition to myeloid neoplasms.","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2023-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3212","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.3212","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

TNFRSF13B mutations are widely associated with common variable immunodeficiency. TNFRSF13B was recently counted among relevant genes associated with childhood-onset of hematological malignancies; nonetheless, its role in acute myeloid leukemia (AML) remains unexplored. We report the study of a family with two cases of AML, sharing a germline TNFRSF13B mutation favoring the formation of a more stable complex with its ligand TNFSF13: a positive regulator of AML-initiating cells. Our data turn the spotlight onto the TNFRSF13B role in AML onset, inserting a new fragment into the complex scenario of a hereditary predisposition to myeloid neoplasms.

Abstract Image

查看原文本刊更多论文

家族性急性髓性白血病中的 TNFRSF13B 基因突变：复杂的遗传易感性中的新元素？

TNFRSF13B 基因突变与常见变异性免疫缺陷广泛相关。最近，TNFRSF13B 被认为是与儿童期血液恶性肿瘤发病相关的基因之一；然而，它在急性髓性白血病（AML）中的作用仍未得到探讨。我们报告了对一个家族两例急性髓性白血病病例的研究，该家族共有一个 TNFRSF13B 基因突变，该基因突变有利于与其配体 TNFSF13 形成更稳定的复合物：TNFSF13 是急性髓性白血病启动细胞的正调控因子。我们的数据使人们注意到 TNFRSF13B 在急性髓细胞性白血病发病中的作用，为骨髓性肿瘤遗传易感性的复杂情况提供了一个新的片段。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.